Immune checkpoint blockade for GBM 1 Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
نویسندگان
چکیده
David A. Reardon, Prafulla C. Gokhale, Sarah R. Klein, Keith L. Ligon, Scott J. Rodig, Shakti H. Ramkissoon, Kristen L. Jones, Amy Saur Conway, Xiaoyun Liao, Jun Zhou, Patrick Y. Wen, Annick D. Van Den Abbeele, F. Stephen Hodi, Lei Qin, Nancy E. Kohl, Arlene H. Sharpe, Glenn Dranoff , and Gordon J. Freeman Center for Neuro-Oncology, Department of Medical Oncology, Belfer Institute for Applied Cancer Science, Lurie Family Imaging Center, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital; Department of Pathology, Brigham and Women’s Hospital; Department of Imaging, Dana-Farber Cancer Institute, Department of Radiology, Brigham and Women’s Hospital, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA
منابع مشابه
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Inhibition of immune checkpoints, including cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and its ligand PD-L1, has demonstrated exciting and durable remissions across a spectrum of malignancies. Combinatorial regimens blocking complementary immune checkpoints further enhance the therapeutic benefit. The activity of these agents for patients with glioblastoma, a generall...
متن کاملNon-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Glioblastoma (GBM) is the most common malignant brain tumor in adults with a median survival of 14.6months. A contributing factor to GBM aggressiveness is the intratumoral expression of the potently immunosuppressive enzyme, indoleamine 2,3 dioxygenase 1 (IDO1). The enzymatic activity of IDO1 is associated with the conversion of tryptophan into downstream kynurenine (Kyn), which has previously ...
متن کاملTransformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
Despite the availability of recently developed chemotherapy regimens, survival times for pancreatic cancer patients remain poor. These patients also respond poorly to immune checkpoint blockade therapies (anti-CTLA-4, anti-PD-L1, anti-PD-1), which suggests the presence of additional immunosuppressive mechanisms in the pancreatic tumour microenvironment (TME). CD40 agonist antibodies (αCD40) pro...
متن کاملCombined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas
BACKGROUND Glioblastoma multiforme (GBM) evades immune surveillance by inducing immunosuppression via receptor-ligand interactions between immune checkpoint molecules. T cell immunoglobulin and mucin domain 3 (Tim-3) is a key checkpoint receptor responsible for exhaustion and dysfunction of T cells and plays a critical role in immunosuppression. Carcinoembryonic antigen-related cell adhesion mo...
متن کاملImmunomodulation: checkpoint blockade etc.
The immune microenvironment is considered a major obstacle to generating an effective antitumor immune response. Checkpoint inhibitors manipulate the co-stimulatory response between antigen-presenting cells and immune cells-or between the tumor and immune cells-to elicit an antitumor immune response that would have otherwise been suppressed. Checkpoint inhibitors have shown great promise in the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2015